Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 1;35(3):246-254.
doi: 10.1097/QCO.0000000000000831.

Neurocysticercosis: an update on diagnosis, treatment, and prevention

Affiliations
Review

Neurocysticercosis: an update on diagnosis, treatment, and prevention

Roberto Pineda-Reyes et al. Curr Opin Infect Dis. .

Abstract

Neurocysticercosis (NCC) is an important cause of neurological disease worldwide, including imported cases in nonendemic countries.

Purpose of review: The purpose of this review is to update information on diagnosis, management, and prevention of neurocysticercosis.

Recent findings: WHO and Infectious Diseases Society of America/American Society of Tropical Medicine and Hygiene guidelines emphasize the importance of corticosteroids and antiparasitic drugs for viable parenchymal disease and single enhancing lesions. Subarachnoid NCC is associated with a high fatality rate unless optimally treated. Advances in subarachnoid NCC include use of prolonged antiparasitic and anti-inflammatory courses and the increasing use of antigen-detection and quantitative PCR assays in diagnosis and follow-up. Emerging data support the safety and efficacy of minimally invasive surgery in ventricular cases. Calcified neurocysticercosis continues to be associated with a high burden of disease. Field studies are demonstrating the feasibility of eradication using a combination of mass chemotherapy for human tapeworms and vaccination/treatment of porcine cysticercosis.

Summary: NCC remains an important and challenging cause of neurological disease with significant morbidity despite advances in treatment and prevention.

PubMed Disclaimer

Similar articles

Cited by

References

    1. White AC, Coyle CM, Rajshekhar V, et al. Diagnosis and treatment of neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis 2018; 66:1159–1163.
    1. WHO guidelines on management of Taenia solium, neurocysticercosis. 2021; Geneva: World Health Organization,
    1. Iqbal J, Ahmad S, Al-Awadhi M, et al. A large case series of neurocysticercosis in Kuwait, a nonendemic Arabian Gulf country in the Middle East region. Microorganisms 2021; 9:1221.
    1. Garcia HH, Gonzalez AE, Gilman RH. Taenia solium cysticercosis and its impact in neurological disease. Clin Microbiol Rev 2020; 33:e00085-19.
    1. Herrick JA, Bustos JA, Clapham P, et al. The Cysticercosis Working Group In Peru. Unique characteristics of epilepsy development in neurocysticercosis. Am J Trop Med Hyg 2020; 103:639–45.

Substances